EMA (EU)
GUIDANCE FINAL
Draft guideline on the investigation of interactions in the gastrointestinal tract
Published: 9/11/2026Detected: 9/11/2026
Summary preview
Provides updated EMA recommendations for investigating and interpreting gastrointestinal absorption-related drug interactions driven by extrinsic factors such as food, gastric pH/acid-reducing agents…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountgastroenterology
clinical
safety
quality
clinical
labeling
manufacturing
#gastrointestinal tract
#drug-drug interaction
#food effect
#gastric pH
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026